IB Acquisition Corp.IBAC

IB Acquisition Corp exited the first quarter of 2026 with $4,634 in cash, negative shareholders’ equity of $1.7 million, and an operating cash burn of $1.3 million for the quarter ended 31 March 2026, according to its 10-Q filed on 15 May 2026. The company’s stated mission is to merge with or acquire a business, but the numbers show a corporation that is currently more adept at burning cash than building enterprise value. (source: IBAC 10-Q, 15 May 2026, https://www.sec.gov/Archives/edgar/data/1998781/000149315226023743/form10-q.htm)

IBAC signed a Business Combination Agreement on 16 March 2026 to merge with GNQ Insilico, contingent on GNQ hitting a $100 million total contract value threshold and securing stockholder approval. The deal documents, including the Business Combination Agreement and a side letter promising introductions to financing sources, were filed with the SEC within days of each other. Yet by 17 April 2026, IBAC’s 425 filing admitted the conditions to consummation had not been satisfied, leaving the merger on ice. (source: IBAC Business Combination Agreement, 16 Mar 2026, https://www.sec.gov/Archives/edgar/data/1998781/000149315226010261/ex2-1.htm)

The company’s 10-Q shows operating losses of $748,177 and a net loss of $639,866 for the quarter to 31 March 2026. Assets stood at $8.5 million against liabilities of $1.8 million, but the $4,634 cash balance tells the real story: IBAC is a capital-light shell with very little dry powder. The diluted share count is 50 million, a structure that invites future dilution if any capital is ever raised. (source: IBAC 10-Q, 15 May 2026, https://www.sec.gov/Archives/edgar/data/1998781/000149315226023743/form10-q.htm)

The SEC filings give a clear view of the company’s state as of 25 July 2026: it is a cash-burning SPAC with a failed merger attempt, a $250,000 bridge that looks large only against the $4,634 balance, and a share base that already dilutes any near-term hope of economic substance. The market can choose to watch this story or ignore it; the evidence does not lie. (source: IBAC SEC filings index, https://www.sec.gov/edgar/browse/?CIK=1998781)

What changed this week is nothing: IBAC’s filings remain the same, the cash remains the same, and the gap between the polished deck and the bank balance remains the same. The company’s 8-Ks on 26 and 27 March 2026 announced the merger with great fanfare, but the formal 425 admission of failure arrived two weeks later. The RegenaLife™ cooperation mentioned in the Business Combination Agreement and side letter is aspirational until definitive agreements are executed, which they have not been. The TCV gate of $100 million remains unmet. The only concrete number that has moved is the date. (source: IBAC 8-K, 26 Mar 2026, https://www.sec.gov/Archives/edgar/data/1998781/000149315226012814/form8-k.htm)

If IBAC can secure stockholder approval, hit the $100 million TCV threshold, and finalise definitive agreements with RegenaLife™, the merger could yet revive. Until then, the company is a cash-burning SPAC with a failed combination, 50 million diluted shares, and a balance sheet that reads like a cautionary tale rather than a prospectus. The next meaningful event would be a revised merger agreement, fresh financing, or a liquidation plan - any of which would require fresh filings and new numbers. (source: IBAC SEC submissions JSON, https://data.sec.gov/submissions/CIK0001998781.json)